Cognition Therapeutics (CGTX) announced that the FDA has aligned on key elements for its pivotal Phase 3 study in Dementia with Lewy Bodies (DLB), targeting participants with mild-to-moderate forms of the no-approved-treatments disease.
Cognition Therapeutics (CGTX) announced that the FDA has aligned on key elements for its pivotal Phase 3 study in Dementia with Lewy Bodies (DLB), targeting participants with mild-to-moderate forms of the no-approved-treatments disease.